Amgen Overview
| Company: | Amgen |
|---|---|
| CEO: | Robert A. Bradway |
| Founded: | Apr 8, 1980 |
| Symbol: | AMGN |
| Exchange: | NASDAQ |
| Industry: | Drug Manufacturers - General |
| Sector: | Healthcare |
| About |
Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's productslude Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen serves healthcare providers,luding physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics and Plexium Amgen wasorporated in 1980 and is headquartered in Thousand Oaks, California. |
-
Ranking:
11 among 2857 companies
-
Address:
One Amgen Center Drive
-
City | State | Country:
Thousand Oak... | CA |
US
-
Phone:
805 447 1000
-
Website:
-
Revenue
Net Income
Employees
Revenue by Segment
Revenue by Region
Executive Salary
Revenue per Employee
Profit per Employee
Income Statement
Operating Income
Research & Development
Tax Rate (%)
Assets & Liabilities | Cash Flow
Total Assets
Total Liabilities
Capital Expenditure
Ratios
Return on Equity (ROE)
Return on Assets (ROA)
Debt to Equity
Profitability
Gross Profit Margin (%)
Operating Income Margin (%)
Net Income Margin (%)
Earning Per Share
EBITDA
Free Cash Flow (FCF)
Valuation
Enterprise value
Enterprise value to Revenue
Enterprise value to EBITDA
Competitors’ Revenue
Frequently Asked Questions
